ZLAB News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

ZL

Mkt Cap

$2.60B

Volume

766.05K

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine CarcinomasBoehringer Ingelheim and Zai Lab announced a clinical collaboration to evaluate a dual DLL3-targeting combination therapy for small cell lung cancer (SCLC) and neuroendocrine carcinomas. The Phase Ib/II study will test obrixtamig, a DLL3/CD3 T-cell engager, combined with zocilurtatug pelitecan (zoci), a DLL3-targeting ADC. Both drugs have shown encouraging early efficacy and favorable safety profiles in previous trials.GlobeNewswire Inc. · Apr 15, 2026

$207B Market Shift: The Race for Fast Track Approval in OncologyThe FDA has accelerated oncology drug approvals with over 50 approvals in 2025 and increased expedited designations in 2026. Multiple biotech companies are advancing cancer treatments through Fast Track and Breakthrough Therapy designations, targeting high-unmet-need solid tumors. Key developments include Oncolytics' pelareorep showing significant survival benefits in colorectal cancer, Relay's zovegalisib receiving Breakthrough designation for breast cancer, MAIA's ateganosine advancing in lung cancer, Zai Lab's AUGTYRO approval in China, and Arrivent's firmonertinib entering pivotal Phase 3 trials for NSCLC.Benzinga · Feb 5, 2026

Zai Lab's Double Whammy: Earnings Miss, Phase 3 SetbackChinese biopharma firm Zai Lab experienced a significant stock decline after disappointing Phase 3 trial results for its gastric cancer drug bemarituzumab and underwhelming quarterly earnings, with weak sales of core products impacting investor confidence.Benzinga · Sep 11, 2025

Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research PrioritiesSeveral biotech companies are advancing cancer research with promising clinical milestones, focusing on innovative immunotherapies and targeted treatments amid rising cancer incidence and potential research funding challenges.Benzinga · Jul 16, 2025

Bispecific Antibody Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsightOver 180 companies are developing 250+ bispecific antibodies targeting complex chronic diseases like cancer and autoimmune disorders, with innovative dual-targeting molecules offering superior therapeutic precision and efficacy.GlobeNewswire Inc. · Jul 7, 2025

argenx and Zai Lab Announce Approval of Efgartigimod Alfa - GlobeNewswireargenx and Zai Lab announced the approval of efgartigimod SC, a subcutaneous injection for the treatment of generalized myasthenia gravis in China. The approval is supported by positive results from the Phase 3 ADAPT-SC study, demonstrating consistent clinical benefit and safety profile compared to the intravenous formulation.GlobeNewswire Inc. · Jul 16, 2024

Top 5 Health Care Stocks That Are Preparing To Pump In FebruaryThe most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro. Here’s the latest list of major oversold players in this sector, having an RSI near or below 30. BIOLASE, Inc. (NASDAQ: BIOL) On Jan. 29, Biolase reported full-year 2023 interim revenue of $48.9 million to $49.2 million, up 1% year-over-year compared to the consensus of $49.21 million. The company’s stock fell around 43% over the past five days ...Benzinga · Feb 9, 2024

Archer-Daniels-Midland, B. Riley Financial And Other Big Stocks Moving Lower In Monday's Pre-Market SessionU.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Monday. Shares of Archer-Daniels-Midland Company (NYSE: ADM) fell sharply in today’s pre-market trading after the company named Ismael Roig as Interim Chief Financial Officer. ADM also said it now expects an adjusted earnings per share of $6.90 for the fiscal year ended Dec. 2023. Archer-Daniels-Midland shares dipped 9.6% to $61.67 in pre-market trading. Here are some big stocks recording losses in today’s pre-market trading session. B. Riley Financial, Inc. (NASDAQ: RILY) shares tumbled 17.5% to $16.63 in pre-market trading. B. Riley Financial issued a statement in response ...Benzinga · Jan 22, 2024

What Makes Zai Lab Limited Unsponsored ADR (ZLAB) a New Buy StockZai Lab Limited Unsponsored ADR (ZLAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.Zacks Investment Research · Dec 22, 2023

Paychex Reports Downbeat Sales, Joins BlackBerry And Other Big Stocks Moving Lower On ThursdayU.S. stocks traded higher, with the Dow Jones index gaining around 200 points on Thursday. Shares of Paychex, Inc. (NASDAQ: PAYX) moved lower during Thursday’s session after the company reported worse-than-expected second-quarter revenue results and issued FY24 guidance. Paychex reported second-quarter FY24 sales growth of 6% year-on-year to $1.26 billion, slightly missing the analyst consensus estimate of $1.27 billion. Adjusted EPS of $1.08 beat the analyst consensus estimate of $1.07, according to Benzinga Pro. Paychex shares fell 5.4% to $120.96 on Thursday. Here are some other big stocks recording losses in today’s session. Jin Medical ...Benzinga · Dec 21, 2023

ZL

ZLABZai Lab Limited American Depositary Shares

ZLAB

Pay with—

Available Balance0.00

Your PositionYou don't own any ZLAB yet.

Related Tickers

Earnings